Pharmesis International (SGX:BFK) 3-Year Revenue Growth Rate : -8.30% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International 3-Year Revenue Growth Rate?

Pharmesis International's Revenue per Share for the six months ended in Dec. 2023 was S$0.12.

During the past 12 months, Pharmesis International's average Revenue per Share Growth Rate was -24.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -8.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was -6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Pharmesis International was 10.70% per year. The lowest was -20.40% per year. And the median was -4.10% per year.

Competitive Comparison of Pharmesis International's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmesis International's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharmesis International's 3-Year Revenue Growth Rate falls into.

Pharmesis International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Pharmesis International (SGX:BFK) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Pharmesis International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharmesis International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International (SGX:BFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Kallang Sector, No. 03-02, Singapore, SGP, 349279

Website

https://www.pharmesis.com

Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its geographical segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International (SGX:BFK) Headlines

From GuruFocus

Certain BlackRock Municipal Closed-End Funds Announce Variable Rate Muni Term Preferred Shares Actions

By Business Wire • 11-02-2023